(Q39388106)

English

Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Andreas Lackner

object named as

Andreas Lackner

4

0 references

Christine Pirker

object named as

Christine Pirker

6

0 references

object named as

Michael Grusch

3

0 references

Józefa Wesierska-Gadek

8

object named as

Józefa Węsierska-Gądek

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Zsuzsanna Bago-Horvath

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Wolfgang Sieghart

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Hubert Hayden

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Oxana Komina

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Andrea Haitel

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Martin Filipits

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Katharina Schmid

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

27 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Neuroendocrinology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

96

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

228-237

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Activity of sunitinib in patients with advanced neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

In vivo activated caspase-3 cleaves PARP-1 in rat liver after administration of the hepatocarcinogen N-nitrosomorpholine (NNM) generating the 85 kDa fragment

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Epidermal growth factor receptor expression and activation in neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear β-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Cytotoxic and biochemical effects of 3,3′,4,4′,5,5′-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Identifiers

10.1159/000337257

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39388106&oldid=1824593806"